We strive to be a global biopharma leader whose mission is
to develop innovative, life-changing medicine
Acute myelogenous leukemia (AML), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and non-Hodgkin lymphoma (NHL)
- U.S. Phase 1 clinical study for AML (monotherapy) in progress
- Additional Phase 1 clinical studies in development for CLL, SLL, NHL in the U.S.
BTK & FLT3 dual inhibitor
Blocks signal transmission by specifically binding to FLT3 and BTK and minimizes off-target effects
Inhibition of FLT3 and BTK within cancer is considered to be superior to competitors based on pre-clinical studies
Oral formulation. Non-clinical GLP-Tox trial proves safety in clinical trials in patients
FDA orphan drug designation: AML
Tyrosine kinase receptors are important for the development of B and T cells. Excessive activity due to the FLT3 mutation was observed in 1/3 of patients with acute myelogenous leukemia.
A component of B cell receptors essential for B cell maturation, survival, and proliferation.
BTK overexpression and mutation are observed in various B cell carcinomas.